Resources
10 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 2/23/2021 (updated 4/4/2024)
RCORP Planning 3 Reference Guide
Posted 12/15/2020 (updated 4/3/2024)
Region 4 RCORP grantees share their experiences.
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session for RCORP Implementation and MAT Expansion grantees was held in the Monument Room on Friday, March 6, 2020, at 11:15 AM
Posted 4/3/2020 (updated 3/28/2024)
This RSV Breakout Session was held in the Supreme Court Room on Wednesday, March 5, 2020, at 2:30 PM
Posted 1/8/2024 (updated 3/28/2024)
The Neonatal Abstinence Syndrome (NAS) Cohort I tip sheet is a result of collaborative efforts of the NAS Cohort I grant recipients. Drawing on the insights and experiences of our grantees, we identified 9 key recommendations. These tips serve not only as a guiding framework for future NAS cohort grantees but also offers valuable guidance to all RCORP grant cohorts. This resource aims to enhance effectiveness and increase the impact of all RCORP grantee initiatives.
Posted 7/26/2023 (updated 3/28/2024)
In this session, we described how we used RCORP-Planning and RCORP-Implementation funds to plan, establish, and grow integrated harm reduction and recovery services in one space, the Fayette County Connection Café. Certified peer recovery coaches facilitated and staff Connection Café services, including peer support mutual aid groups, syringe services programming, street outreach, harm reduction vending machine, and 24-hour access to Naloxone.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.
Posted 3/21/2023 (updated 3/27/2024)
Training materials A Stimulating Talk